MBX Biosciences, a clinical-stage biopharmaceutical company based in Carmel, Indiana, focuses on precision peptide therapies for endocrine and metabolic disorders and went public on September 13, 2024. Its product candidates include MBX 2109, MBX 1416, and MBX 4291, targeting various hormone-related conditions.